Pfizer Inc. (PFE)
Chart Events
Performance Outlook
| Previous Close | 39.35 |
| Open | 39.44 |
| Bid | 39.75 x 1200 |
| Ask | 39.76 x 1000 |
| Day's Range | 39.31 - 39.84 |
| 52 Week Range | 29.99 - 43.08 |
| Volume | 7,745,097 |
| Avg. Volume | 30,371,570 |
| Market Cap | 222.178B |
| Beta (5Y Monthly) | 0.67 |
| PE Ratio (TTM) | 20.18 |
| EPS (TTM) | 1.97 |
| Earnings Date | Jul 26, 2021 - Jul 30, 2021 |
| Forward Dividend & Yield | 1.56 (3.96%) |
| Ex-Dividend Date | May 06, 2021 |
| 1y Target Est | 42.46 |
Fair Value
Related Research
- Morningstar | A Weekly Summary of Stock Ideas and Developments in the Companies We Cover
- Analyst Report: Pfizer Inc.
- Editor's PickYahoo Finance Video
Dr. Fauci: We are 'in a race' between the vaccine and virus
Dr. Fauci testifies on the latest coronavirus developments. Yahoo Finance’s Jessica Smith shares the details.
- Reuters
UPDATE 1-Swiss aim to re-open economy, donate AstraZeneca COVID-19 shots
Switzerland aims to expand its economic re-opening and may donate millions of AstraZeneca COVID-19 vaccine doses to developing countries as the Alpine nation grows increasingly confident it is beating back the pandemic. Health Minister Alain Berset on Wednesday said the country may give 3 million of 5.4 million AstraZeneca doses it has reserved to the COVAX vaccine sharing programme. Switzerland has enough mRNA shots from producers including Pfizer and Moderna to cover 2021 and 2022, Berset said.
- Benzinga
Pfizer Rebuffs Report On COVID-19 Vaccine Production In South Korea With Samsung BioLogics: Reuters
According to Reuters, Samsung BioLogics Co Ltd and Pfizer Inc (NYSE: PFE) have denied reports claiming they were working together to produce the COVID-19 vaccine developed in partnership with BioNTech SE (NASDAQ: BNTX) in South Korea. The Korea Economic Daily reported earlier that the biotech arm of Samsung Group had been revamping production lines at its plant in Songdo to produce the Pfizer/BioNTech vaccine. The report quoted an unnamed high-level government official and said that the plant could make up to 1 billion doses per year, with production starting from August. Samsung BioLogics said in a one-line filing to the stock exchange that the report was "not factual." Pfizer said its current production strategy was centered on its two dedicated supply lines in the U.S. and Europe. "At this time, we are not in discussions for any additional manufacturing outside these established supply lines for this vaccine," Pfizer said in a statement. South Korea has secured 192 million doses, enough to vaccinate all 52 million residents twice over. But President Moon Jae-in is under pressure to secure more and faster deliveries of U.S.-made shots as he heads for his first summit with U.S. President Joe Biden next week. Price Action: PFE shares are up 0.23% at $39.44 during the premarket session on the last check Wednesday. See more from BenzingaClick here for options trades from BenzingaFDA Outlines Plan For Restarting Facility Inspections Halted Due To PandemicUK's NICE Provisionally Rejects Coverage Of Pfizer-Merck KGaA's Bavencio As First-Line Therapy For Bladder Cancer© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
